[HTML][HTML] Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single …
H Ehsan, M Robinson, PM Voorhees, K Cassetta… - Life, 2024 - mdpi.com
Selinexor (Seli) is a first-in-class, oral selective inhibitor of the nuclear export protein,
exportin-1 (XPO1). Seli exhibits its antitumor effect through the blockage of XPO1, which …
exportin-1 (XPO1). Seli exhibits its antitumor effect through the blockage of XPO1, which …
Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study …
H Ehsan, M Robinson, P Voorhees… - Life (Basel …, 2024 - europepmc.org
Selinexor (Seli) is a first-in-class, oral selective inhibitor of the nuclear export protein,
exportin-1 (XPO1). Seli exhibits its antitumor effect through the blockage of XPO1, which …
exportin-1 (XPO1). Seli exhibits its antitumor effect through the blockage of XPO1, which …
[HTML][HTML] Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single …
H Ehsan, M Robinson, PM Voorhees, K Cassetta… - Life, 2024 - ncbi.nlm.nih.gov
Selinexor (Seli) is a first-in-class, oral selective inhibitor of the nuclear export protein,
exportin-1 (XPO1). Seli exhibits its antitumor effect through the blockage of XPO1, which …
exportin-1 (XPO1). Seli exhibits its antitumor effect through the blockage of XPO1, which …
Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study …
H Ehsan, M Robinson, PM Voorhees… - Life (2075 …, 2024 - search.ebscohost.com
Selinexor (Seli) is a first-in-class, oral selective inhibitor of the nuclear export protein,
exportin-1 (XPO1). Seli exhibits its antitumor effect through the blockage of XPO1, which …
exportin-1 (XPO1). Seli exhibits its antitumor effect through the blockage of XPO1, which …
Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study …
H Ehsan, M Robinson, PM Voorhees… - Life (Basel …, 2024 - pubmed.ncbi.nlm.nih.gov
Selinexor (Seli) is a first-in-class, oral selective inhibitor of the nuclear export protein,
exportin-1 (XPO1). Seli exhibits its antitumor effect through the blockage of XPO1, which …
exportin-1 (XPO1). Seli exhibits its antitumor effect through the blockage of XPO1, which …
Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study …
H Ehsan, M Robinson, PM Voorhees, K Cassetta… - Life, 2024 - ui.adsabs.harvard.edu
Selinexor (Seli) is a first-in-class, oral selective inhibitor of the nuclear export protein,
exportin-1 (XPO1). Seli exhibits its antitumor effect through the blockage of XPO1, which …
exportin-1 (XPO1). Seli exhibits its antitumor effect through the blockage of XPO1, which …
Efficacy of Selinexor in Relapsed/Refractory Multiple Myeloma (RRMM) Patients with del17p and Other High-Risk Abnormalities (A Retrospective Single-Center Study …
H Ehsan, M Robinson, PM Voorhees… - Life (Basel …, 2024 - europepmc.org
Selinexor (Seli) is a first-in-class, oral selective inhibitor of the nuclear export protein,
exportin-1 (XPO1). Seli exhibits its antitumor effect through the blockage of XPO1, which …
exportin-1 (XPO1). Seli exhibits its antitumor effect through the blockage of XPO1, which …